Qol Holdings Co.,Ltd.【JP:3034】Stock Price

Cure All Holdings operates three main business segments. First, in the pharmacy business, 21 consolidated subsidiaries including Cure All Corporation manage insurance pharmacies. This supports the provision of healthcare services to local communities.

Second, in the BPO (Business Process Outsourcing) business, six companies including Apo Plus Station Corporation engage in CSO (Contract Sales Organization) operations, CRO (Contract Research Organization) operations, staffing and dispatch services, publishing-related business, and other services. This addresses diverse needs within the pharmaceutical industry.

Third, in the pharmaceutical manufacturing business, two companies including Daiichi Sankyo Esfa Corporation manufacture and sell pharmaceutical products. This segment contributes to medical advancement by handling pharmaceutical development through sales in an integrated manner. Through these operations, Cure All Holdings provides a wide range of healthcare and health-related services.

Cure All Holdings aims to grow as a comprehensive healthcare company, with medium-term targets of consolidated net sales of 300 billion yen and operating profit of 24 billion yen. In April 2025, the company acquired additional shares in Daiichi Sankyo Espha Co., Ltd., increasing its ownership stake to 80%. Through this acquisition, the company seeks to improve quality, expand scale, and drive further growth.

In the pharmacy business, the company focuses on home care and facility dispensing to realize patient-centered healthcare. It has also opened "Cure All Anytime Pharmacy," an online specialty pharmacy, and leverages digital transformation to enhance pharmacy convenience. Additionally, the company pursues cost optimization and productivity improvements to ensure sustainable healthcare delivery.

In the BPO business, the company responds to growing demand for MR dispatch services by increasing MR recruitment and deployment numbers. In the CRO business, it advances new customer acquisition and digital transformation initiatives. In the staffing business, it strengthens customer acquisition and talent development. These efforts aim to expand business scale and improve productivity.

In the pharmaceutical business, the company prioritizes quality control and stable supply of medicines. Through the consolidation of Daiichi Sankyo Espha as a group company, it expands its AG product lineup. By leveraging synergies with the pharmacy and BPO businesses and broadening its product portfolio, the company seeks to increase market share.